Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 31 March, 2008

Almac Clinical Technologies

Almac Showcases Fully Integrated Suite of e-Tec...

YARDLEY, PA -- (MARKETWIRE) -- 03/31/08 --  On April 14-16, Almac
Clinical Technologies will be showcasing its fully integrated suite
of e-clinical technologies at the joint conference "Partnerships with
CROs" and "EDC & Beyond" (co-located at the Mandalay Bay Resort and
Casino in Las Vegas). "The built-in integration between our EDC and
IVR/IXRS (web and phone) solution allows sponsors to benefit from
workflow and cost efficiencies when working with Almac. Our
integrated technologies dramatically reduce redundant data entry,
time spent reconciling conflicting data, and help speed a study to
data lock," explains Jim Murphy, President of Almac Clinical

Almac's ability to provide a full range of integrated clinical
technology services leads to unique opportunities to partner with
CROs. Almac is looking at the CRO Partnerships meeting as an
opportunity to explore relationships with Clinical CROs, given the
value such arrangements would provide to clients.

"It is highly beneficial for sponsors to work with a clinical CRO and
a reputable technology vendor that work as part of an alliance. It
allows both the clinical CRO and the sponsor the flexibility to
best-of-breed technology without taking on the fixed costs associated
with developing and maintaining expensive technologies in-house. It's
an arrangement that works out great for the CRO and tech provider,
even more so for the client who receives the best solution for its

Fritz Haas, Vice President of New Products and Services, will be
presenting at EDC & Beyond on Tuesday afternoon about the role of EDC
technology as well as the value of integration between EDC and other
clinical technologies. Haas will also assess the current state of EDC
technology and discuss future possibilities for the technology.

"EDC is now at a tipping point in terms of adoption by sponsors for
clinical trials. In the past, EDC was looked upon mainly as a
solution for late stage trials involving large volumes of data or
complex designs. Today, however, sponsors are adopting early stage
methodologies such as translational medicine and 'learn and confirm'
which require data sharing between scientists and clinicians involved
in early stage development from discovery through proof-of-concept in
Phase II. Having all data in electronic form early for dissemination
and analysis across teams is vital to improving R&D productivity."

Come visit Almac at booth #412 in Las Vegas, where you'll have the
opportunity to demo a range of e-technology solutions and win various

About Almac

Almac Clinical Technologies is a division of the Almac Group that
specializes in interactive technology and service solutions to
increase the quality and efficiency of the clinical trial process.
Our solutions include Interactive Voice and Web Response Systems
(IXRS(TM)) for patient randomization; tracking and clinical supply
management; iTrial EDC for electronic case report form data
collection; electronic patient reported outcome data collection; and
web drug reconciliation.

The Almac Group comprises five closely integrated divisions offering
a broad range of services from R&D, translational genomic services,
API manufacture, formulation development, clinical trial supply and
technology (IVRS/EDC), to commercial-scale manufacture. Almac
services to over 600 companies including all the world leaders in the
pharmaceutical and biotech sectors. The company employs over 2,000
individuals and is headquartered in Craigavon, Northern Ireland. US
operations are based in Pennsylvania, North Carolina and California.

Meghan Adams
T: (001) 267-685-4284
E: [email protected]

a d v e r t i s e m e n t